{"hands_on_practices": [{"introduction": "To effectively use antagonists in a clinical setting, it is essential to first understand their mechanism of action at the molecular level. This practice problem guides you through the foundational principles of competitive antagonism, where an antagonist competes with an agonist for the same receptor binding site [@problem_id:4917031]. By deriving the relationship and calculating the resulting physiological effect, you will solidify your understanding of how competitive blockers quantitatively shift an agonist's potency, a hallmark of this class of drugs.", "problem": "A selective $\\beta_1$-adrenergic receptor agonist produces a chronotropic (heart rate increasing) response described by the rectangular hyperbola model $E = \\dfrac{E_{\\max}[A]}{EC_{50} + [A]}$, where $E$ is the increase in heart rate above baseline, $E_{\\max}$ is the maximum achievable increase, $[A]$ is the agonist concentration, and $EC_{50}$ is the half-maximal effective concentration (EC50). Consider the introduction of a competitive antagonist at concentration $[I]$ that binds to the same site with equilibrium dissociation constant $K_{B}$ (the antagonist equilibrium dissociation constant). Using the law of mass action and the definition of competitive binding at a single site, derive the expression for the agonist effect $E([A],[I])$ in the presence of the antagonist in terms of $E_{\\max}$, $EC_{50}$, $[A]$, $[I]$, and $K_{B}$. Then apply the derived expression to a $\\beta_1$-mediated chronotropic response with the following parameters: baseline heart rate $H_{0} = 70\\,\\mathrm{beats\\,min^{-1}}$, $E_{\\max} = 50\\,\\mathrm{beats\\,min^{-1}}$, $EC_{50} = 5\\,\\mathrm{nM}$, agonist concentration $[A] = 8\\,\\mathrm{nM}$, antagonist concentration $[I] = 20\\,\\mathrm{nM}$, and $K_{B} = 10\\,\\mathrm{nM}$. Compute the final heart rate $H = H_{0} + E([A],[I])$. Express the final heart rate in $\\mathrm{beats\\,min^{-1}}$ and round your answer to four significant figures.", "solution": "The starting point is the empirical Emax model $E = \\dfrac{E_{\\max}[A]}{EC_{50} + [A]}$, which arises under the assumptions that the effect is proportional to receptor occupancy (or a monotonic function thereof) and that the agonist produces a surmountable, saturable response.\n\nTo incorporate a competitive antagonist, we begin from the law of mass action for binding at a single site. Let the agonist be denoted $A$ with equilibrium dissociation constant $K_{A}$, and the antagonist be denoted $I$ with equilibrium dissociation constant $K_{B}$. For competitive binding to the same site, the fraction of receptors occupied by the agonist, denoted $f_{A}$, can be derived from the ratio of bound to total receptor under equilibrium. The standard result from mass-action binding for two ligands competing for the same site is\n$$\nf_{A} = \\frac{\\frac{[A]}{K_{A}}}{1 + \\frac{[A]}{K_{A}} + \\frac{[I]}{K_{B}}}.\n$$\nThis can be rewritten by multiplying numerator and denominator by $K_{A}$ to eliminate the explicit ratios:\n$$\nf_{A} = \\frac{[A]}{K_{A}\\left(1 + \\frac{[I]}{K_{B}}\\right) + [A]}.\n$$\nUnder the assumption that effect is proportional to functional agonist occupancy (with a proportionality that saturates at $E_{\\max}$), the effect in the presence of a competitive antagonist becomes\n$$\nE([A],[I]) = E_{\\max}\\, f_{A} = \\frac{E_{\\max}[A]}{K_{A}\\left(1 + \\frac{[I]}{K_{B}}\\right) + [A]}.\n$$\nIn the simple Emax model without spare receptors or nonlinear transduction, the $EC_{50}$ equals the apparent potency related to $K_{A}$. Identifying $EC_{50}$ with $K_{A}$ under these conditions yields\n$$\nE([A],[I]) = \\frac{E_{\\max}[A]}{EC_{50}\\left(1 + \\frac{[I]}{K_{B}}\\right) + [A]}.\n$$\nThis shows that the presence of a competitive antagonist increases the apparent $EC_{50}$ by the factor $\\left(1 + \\dfrac{[I]}{K_{B}}\\right)$ while leaving $E_{\\max}$ unchanged, consistent with surmountable antagonism.\n\nWe now apply this expression to the given $\\beta_1$-mediated chronotropic response. The final heart rate $H$ is the baseline plus the drug-induced increase:\n$$\nH = H_{0} + E([A],[I]).\n$$\nSubstitute the provided values symbolically into the expression for $E([A],[I])$:\n$$\nE([A],[I]) = \\frac{E_{\\max}[A]}{EC_{50}\\left(1 + \\frac{[I]}{K_{B}}\\right) + [A]}.\n$$\nWith $H_{0} = 70\\,\\mathrm{beats\\,min^{-1}}$, $E_{\\max} = 50\\,\\mathrm{beats\\,min^{-1}}$, $EC_{50} = 5\\,\\mathrm{nM}$, $[A] = 8\\,\\mathrm{nM}$, $[I] = 20\\,\\mathrm{nM}$, and $K_{B} = 10\\,\\mathrm{nM}$, compute the antagonist-induced potency shift:\n$$\n1 + \\frac{[I]}{K_{B}} = 1 + \\frac{20}{10} = 3.\n$$\nThus the apparent half-maximal effective concentration is $EC_{50,\\mathrm{app}} = EC_{50} \\times 3 = 5 \\times 3 = 15\\,\\mathrm{nM}$, and the effect becomes\n$$\nE([A],[I]) = \\frac{50 \\times 8}{15 + 8} = \\frac{400}{23}.\n$$\nNumerically, \n$$\n\\frac{400}{23} \\approx 17.3913043478\\,\\mathrm{beats\\,min^{-1}}.\n$$\nTherefore,\n$$\nH = 70 + 17.3913043478 \\approx 87.3913043478\\,\\mathrm{beats\\,min^{-1}}.\n$$\nRounded to four significant figures as requested, the final heart rate is $87.39\\,\\mathrm{beats\\,min^{-1}}$.", "answer": "$$\\boxed{87.39}$$", "id": "4917031"}, {"introduction": "Drug selectivity is a cornerstone of modern pharmacotherapy, allowing us to target specific receptors to achieve a desired effect while avoiding others to minimize side effects. However, selectivity is rarely absolute and is often dose-dependent. This exercise [@problem_id:4917029] presents a clinically relevant scenario, asking you to determine the threshold dose at which a cardioselective $\\beta_1$ blocker begins to cause significant blockade of $\\beta_2$ receptors, which could be dangerous in a patient with asthma. This practice bridges receptor theory with practical risk-benefit analysis, a critical skill for any pharmacologist.", "problem": "A new cardioselective $\\beta_{1}$-adrenoceptor antagonist (working name: Cardiolex) is being considered for use in patients with moderate asthma. Cardiolex exhibits simple $1:1$ reversible binding to receptors governed by the law of mass action and is competitive with endogenous catecholamines, which you may neglect at rest for the purpose of this calculation. Assume that target tissue (airway and sinoatrial node) free drug concentration equals the steady-state average free plasma concentration.\n\nKnown properties of Cardiolex and the patient population are as follows:\n- Dissociation constant at $\\beta_{1}$ receptors: $K_{d,\\beta_{1}} = 1\\ \\mathrm{nM}$.\n- Dissociation constant at $\\beta_{2}$ receptors: $K_{d,\\beta_{2}} = 50\\ \\mathrm{nM}$.\n- Molecular weight: $\\mathrm{MW} = 300\\ \\mathrm{g}\\ \\mathrm{mol}^{-1}$.\n- Oral bioavailability: $F = 0.90$.\n- Unbound (free) fraction in plasma: $f_{u} = 0.10$.\n- Apparent systemic clearance: $\\mathrm{CL} = 20\\ \\mathrm{L}\\ \\mathrm{h}^{-1}$.\n- Dosing interval at steady state: $\\tau = 12\\ \\mathrm{h}$.\n\nIn moderate asthma, define “clinically significant $\\beta_{2}$ antagonism” as occurring when the fractional occupancy of $\\beta_{2}$ receptors by Cardiolex reaches $\\theta_{\\beta_{2}}^{\\ast} = 0.20$.\n\nUsing only fundamental receptor binding based on the law of mass action and steady-state mass balance for a one-compartment model with linear clearance (no saturation), derive from first principles and compute the minimal per-dose amount $D_{\\text{thresh}}$ (oral dose given every $\\tau$ hours at steady state) at which $\\theta_{\\beta_{2}} = \\theta_{\\beta_{2}}^{\\ast}$. Express the final dose in $\\mathrm{mg}$ and round your answer to three significant figures.", "solution": "The problem asks for the minimal oral dose, $D_{\\text{thresh}}$, administered every $\\tau$ hours, that results in a clinically significant fractional occupancy of $\\beta_{2}$ adrenoceptors, defined as $\\theta_{\\beta_{2}}^{\\ast} = 0.20$. The solution requires a multi-step derivation that connects the pharmacodynamic effect (receptor occupancy) to the pharmacokinetic properties of the drug and the prescribed dosing regimen.\n\nThe derivation proceeds in three main stages:\n1.  **Pharmacodynamics**: Determine the required free drug concentration, $[L]_{\\text{free}}$, that achieves the target fractional occupancy $\\theta_{\\beta_{2}}^{\\ast}$ at the $\\beta_{2}$ receptors.\n2.  **Pharmacokinetics**: Relate this required free drug concentration to the necessary average total drug concentration at steady state, $C_{ss,avg}$, in the plasma.\n3.  **Dosing Calculation**: Use the steady-state mass balance equation for a one-compartment model to calculate the oral dose, $D_{\\text{thresh}}$, required to maintain this $C_{ss,avg}$.\n\n**Step 1: Derivation of Required Free Drug Concentration**\n\nThe binding of a drug (ligand, $L$) to a receptor, $R$, is a reversible process governed by the law of mass action:\n$$ L + R \\rightleftharpoons LR $$\nThe dissociation constant, $K_d$, is defined as:\n$$ K_d = \\frac{[L][R]}{[LR]} $$\nwhere $[L]$ is the concentration of the free ligand, $[R]$ is the concentration of the free receptor, and $[LR]$ is the concentration of the ligand-receptor complex.\n\nFractional occupancy, $\\theta$, is the fraction of total receptors ($[R]_{\\text{total}} = [R] + [LR]$) that are bound by the ligand:\n$$ \\theta = \\frac{[LR]}{[R]_{\\text{total}}} = \\frac{[LR]}{[R] + [LR]} $$\nBy rearranging the $K_d$ equation, we have $[R] = \\frac{K_d [LR]}{[L]}$. Substituting this into the equation for $\\theta$:\n$$ \\theta = \\frac{[LR]}{\\frac{K_d [LR]}{[L]} + [LR]} $$\nDividing the numerator and denominator by $[LR]$ yields the Hill-Langmuir equation:\n$$ \\theta = \\frac{[L]}{K_d + [L]} $$\nWe are given that clinically significant $\\beta_{2}$ antagonism occurs when the fractional occupancy of $\\beta_{2}$ receptors, $\\theta_{\\beta_{2}}$, reaches the threshold $\\theta_{\\beta_{2}}^{\\ast} = 0.20$. The problem states that the free drug concentration in the target tissue is equal to the steady-state average free plasma concentration, which we denote as $[C]_{\\text{free,ss,avg}}$. We can set $[L] = [C]_{\\text{free,ss,avg}}$ and apply the equation to the $\\beta_{2}$ receptor:\n$$ \\theta_{\\beta_{2}}^{\\ast} = \\frac{[C]_{\\text{free,ss,avg}}}{K_{d,\\beta_{2}} + [C]_{\\text{free,ss,avg}}} $$\nWe must solve for the required concentration, $[C]_{\\text{free,ss,avg}}$.\n$$ \\theta_{\\beta_{2}}^{\\ast} (K_{d,\\beta_{2}} + [C]_{\\text{free,ss,avg}}) = [C]_{\\text{free,ss,avg}} $$\n$$ \\theta_{\\beta_{2}}^{\\ast} K_{d,\\beta_{2}} = [C]_{\\text{free,ss,avg}} (1 - \\theta_{\\beta_{2}}^{\\ast}) $$\n$$ [C]_{\\text{free,ss,avg}} = K_{d,\\beta_{2}} \\left( \\frac{\\theta_{\\beta_{2}}^{\\ast}}{1 - \\theta_{\\beta_{2}}^{\\ast}} \\right) $$\nSubstituting the given values $K_{d,\\beta_{2}} = 50\\ \\mathrm{nM}$ and $\\theta_{\\beta_{2}}^{\\ast} = 0.20$:\n$$ [C]_{\\text{free,ss,avg}} = (50\\ \\mathrm{nM}) \\left( \\frac{0.20}{1 - 0.20} \\right) = (50\\ \\mathrm{nM}) \\left( \\frac{0.20}{0.80} \\right) = (50\\ \\mathrm{nM}) \\left( \\frac{1}{4} \\right) = 12.5\\ \\mathrm{nM} $$\n\n**Step 2: Conversion to Average Total Plasma Concentration**\n\nThe average total plasma concentration at steady state, $C_{ss,avg}$, is related to the average free concentration, $[C]_{\\text{free,ss,avg}}$, by the unbound fraction in plasma, $f_u$.\n$$ [C]_{\\text{free,ss,avg}} = f_u \\cdot C_{ss,avg} $$\nTherefore, the required average total concentration is:\n$$ C_{ss,avg} = \\frac{[C]_{\\text{free,ss,avg}}}{f_u} $$\nSubstituting the values $[C]_{\\text{free,ss,avg}} = 12.5\\ \\mathrm{nM}$ and $f_u = 0.10$:\n$$ C_{ss,avg} = \\frac{12.5\\ \\mathrm{nM}}{0.10} = 125\\ \\mathrm{nM} $$\n\n**Step 3: Calculation of the Threshold Dose**\n\nFor a one-compartment model with linear clearance at steady state, the rate of drug administration that becomes systemically available is equal to the rate of drug elimination. The average rate of drug entering the systemic circulation from an oral dose $D$ with bioavailability $F$ given every dosing interval $\\tau$ is $\\frac{F \\cdot D}{\\tau}$. The average rate of elimination is the product of the systemic clearance, $\\mathrm{CL}$, and the average steady-state plasma concentration, $C_{ss,avg}$.\n$$ \\text{Rate in} = \\text{Rate out} $$\n$$ \\frac{F \\cdot D_{\\text{thresh}}}{\\tau} = \\mathrm{CL} \\cdot C_{ss,avg} $$\nWe can now solve for the threshold dose, $D_{\\text{thresh}}$:\n$$ D_{\\text{thresh}} = \\frac{\\mathrm{CL} \\cdot C_{ss,avg} \\cdot \\tau}{F} $$\nBefore substituting the numerical values, we must ensure all units are consistent. We will calculate the dose in grams first, and then convert to milligrams.\nThe given parameters are:\n- $\\mathrm{CL} = 20\\ \\mathrm{L}\\ \\mathrm{h}^{-1}$\n- $C_{ss,avg} = 125\\ \\mathrm{nM} = 125 \\times 10^{-9}\\ \\mathrm{mol}\\ \\mathrm{L}^{-1}$\n- $\\tau = 12\\ \\mathrm{h}$\n- $F = 0.90$\n- $\\mathrm{MW} = 300\\ \\mathrm{g}\\ \\mathrm{mol}^{-1}$\n\nFirst, we calculate the dose in moles:\n$$ D_{\\text{thresh}} (\\text{in mol}) = \\frac{(20\\ \\mathrm{L}\\ \\mathrm{h}^{-1}) \\cdot (125 \\times 10^{-9}\\ \\mathrm{mol}\\ \\mathrm{L}^{-1}) \\cdot (12\\ \\mathrm{h})}{0.90} $$\n$$ D_{\\text{thresh}} (\\text{in mol}) = \\frac{20 \\cdot 125 \\cdot 12}{0.90} \\times 10^{-9}\\ \\mathrm{mol} = \\frac{30000}{0.90} \\times 10^{-9}\\ \\mathrm{mol} = \\frac{100000}{3} \\times 10^{-9}\\ \\mathrm{mol} $$\nNext, we convert this molar amount to a mass in grams using the molecular weight $\\mathrm{MW}$:\n$$ D_{\\text{thresh}} (\\text{in g}) = D_{\\text{thresh}} (\\text{in mol}) \\times \\mathrm{MW} $$\n$$ D_{\\text{thresh}} (\\text{in g}) = \\left(\\frac{100000}{3} \\times 10^{-9}\\ \\mathrm{mol}\\right) \\times (300\\ \\mathrm{g}\\ \\mathrm{mol}^{-1}) $$\n$$ D_{\\text{thresh}} (\\text{in g}) = \\frac{100000 \\times 300}{3} \\times 10^{-9}\\ \\mathrm{g} = 100000 \\times 100 \\times 10^{-9}\\ \\mathrm{g} = 10^5 \\times 10^2 \\times 10^{-9}\\ \\mathrm{g} $$\n$$ D_{\\text{thresh}} (\\text{in g}) = 10^7 \\times 10^{-9}\\ \\mathrm{g} = 10^{-2}\\ \\mathrm{g} = 0.01\\ \\mathrm{g} $$\nFinally, we convert the dose from grams to milligrams, as requested by the problem statement.\n$$ D_{\\text{thresh}} (\\text{in mg}) = 0.01\\ \\mathrm{g} \\times \\frac{1000\\ \\mathrm{mg}}{1\\ \\mathrm{g}} = 10\\ \\mathrm{mg} $$\nThe problem requires the answer to be rounded to three significant figures. The calculated value is exactly $10$. To express this with three significant figures, we write $10.0$.\n\nThe minimal per-dose amount $D_{\\text{thresh}}$ required to achieve a fractional occupancy of $0.20$ at $\\beta_{2}$ receptors is $10.0\\ \\mathrm{mg}$.", "answer": "$$\\boxed{10.0}$$", "id": "4917029"}, {"introduction": "The paradigm of \"one dose fits all\" is increasingly being replaced by personalized medicine, which accounts for individual patient variability. A major source of this variability is genetics, particularly in the genes that code for drug-metabolizing enzymes. This advanced problem [@problem_id:4916997] delves into the field of pharmacogenetics by exploring how a common genetic variation in the CYP2D6 enzyme dramatically alters the pharmacokinetics of the β-blocker metoprolol. By calculating the necessary dose adjustment for a \"poor metabolizer,\" you will learn to apply pharmacokinetic principles to ensure patient safety and efficacy in the face of genetic differences.", "problem": "Metoprolol is a cardioselective $\\beta_{1}$ adrenergic receptor antagonist (β-blocker) whose hepatic metabolism is dominated by Cytochrome P450 2D6 (CYP2D6). Consider two genotype-defined patient groups: extensive metabolizers and poor metabolizers of CYP2D6. In extensive metabolizers, systemic clearance and oral bioavailability are $CL_{\\mathrm{EM}} = 60 \\, \\mathrm{L/h}$ and $F_{\\mathrm{EM}} = 0.50$, respectively. The fraction of total systemic clearance mediated by CYP2D6 is $f_{m} = 0.70$, with the remainder attributed to non-CYP2D6 pathways that are unchanged across genotypes. In poor metabolizers, CYP2D6 metabolic activity is reduced to $0.10$ of extensive metabolizer activity, and oral bioavailability increases to $F_{\\mathrm{PM}} = 0.85$ due to reduced first-pass metabolism. Assume linear pharmacokinetics and that distribution processes do not differ between groups. Using fundamental pharmacokinetic definitions of clearance, bioavailability, and exposure, explain the mechanistic role of CYP2D6 in metoprolol clearance and derive an expression for the oral dose adjustment factor $R$ required in poor metabolizers to achieve the same area under the plasma concentration–time curve $AUC_{0-\\infty}$ after a single dose as extensive metabolizers. Then calculate the numerical value of $R$ given the data. Express $R$ as a unitless decimal factor and round your answer to three significant figures.", "solution": "The primary objective is to determine the oral dose adjustment factor, $R$, for poor metabolizers (PM) of metoprolol to achieve the same systemic drug exposure as extensive metabolizers (EM). Systemic exposure is quantified by the area under the plasma concentration-time curve from time zero to infinity, denoted as $AUC_{0-\\infty}$.\n\nThe fundamental relationship for $AUC_{0-\\infty}$ following a single oral dose, $D$, under the assumption of linear pharmacokinetics is given by:\n$$AUC_{0-\\infty} = \\frac{F \\cdot D}{CL}$$\nwhere $F$ is the oral bioavailability and $CL$ is the total systemic clearance.\n\nWe are tasked with finding the dose for a poor metabolizer, $D_{\\mathrm{PM}}$, such that the resulting exposure, $AUC_{\\mathrm{PM}}$, is equal to the exposure in an extensive metabolizer, $AUC_{\\mathrm{EM}}$, who receives a dose $D_{\\mathrm{EM}}$.\nThe condition is:\n$$AUC_{\\mathrm{PM}} = AUC_{\\mathrm{EM}}$$\nSubstituting the fundamental equation for AUC into this condition, we get:\n$$\\frac{F_{\\mathrm{PM}} \\cdot D_{\\mathrm{PM}}}{CL_{\\mathrm{PM}}} = \\frac{F_{\\mathrm{EM}} \\cdot D_{\\mathrm{EM}}}{CL_{\\mathrm{EM}}}$$\nThe dose adjustment factor, $R$, is defined as the ratio of the PM dose to the EM dose, such that $D_{\\mathrm{PM}} = R \\cdot D_{\\mathrm{EM}}$. Substituting this definition into the equality gives:\n$$\\frac{F_{\\mathrm{PM}} \\cdot (R \\cdot D_{\\mathrm{EM}})}{CL_{\\mathrm{PM}}} = \\frac{F_{\\mathrm{EM}} \\cdot D_{\\mathrm{EM}}}{CL_{\\mathrm{EM}}}$$\nAssuming the dose $D_{\\mathrm{EM}}$ is non-zero, it can be cancelled from both sides. We then solve for $R$:\n$$R = \\frac{F_{\\mathrm{EM}}}{F_{\\mathrm{PM}}} \\cdot \\frac{CL_{\\mathrm{PM}}}{CL_{\\mathrm{EM}}}$$\nThis expression shows that the dose adjustment factor depends on the ratios of bioavailability and total systemic clearance between the two genotypes.\n\nNext, we must explain the mechanistic role of CYP2D6 and derive an expression for the clearance ratio, $\\frac{CL_{\\mathrm{PM}}}{CL_{\\mathrm{EM}}}$. Total systemic clearance ($CL$) is the sum of all parallel elimination pathways. For metoprolol, this can be partitioned into the clearance mediated by CYP2D6 ($CL_{CYP2D6}$) and the clearance mediated by all other, non-CYP2D6 pathways ($CL_{non-CYP2D6}$).\n\nFor an extensive metabolizer (EM), the total systemic clearance is:\n$$CL_{\\mathrm{EM}} = CL_{CYP2D6, EM} + CL_{non-CYP2D6}$$\nWe are given that the fraction of total systemic clearance mediated by CYP2D6 is $f_{m} = 0.70$. This allows us to express the component clearances in terms of $CL_{\\mathrm{EM}}$:\n$$CL_{CYP2D6, EM} = f_{m} \\cdot CL_{\\mathrm{EM}}$$\n$$CL_{non-CYP2D6} = (1 - f_{m}) \\cdot CL_{\\mathrm{EM}}$$\nThe problem states that the non-CYP2D6 pathways are unchanged across genotypes, so $CL_{non-CYP2D6}$ is the same for PMs and EMs.\n\nFor a poor metabolizer (PM), CYP2D6 metabolic activity is reduced to $0.10$ of the extensive metabolizer activity. This directly scales the CYP2D6-mediated clearance:\n$$CL_{CYP2D6, PM} = 0.10 \\cdot CL_{CYP2D6, EM}$$\nThe total systemic clearance in a PM is the sum of the reduced CYP2D6 clearance and the unchanged non-CYP2D6 clearance:\n$$CL_{\\mathrm{PM}} = CL_{CYP2D6, PM} + CL_{non-CYP2D6}$$\nNow, we substitute the expressions in terms of $f_m$ and $CL_{\\mathrm{EM}}$:\n$$CL_{\\mathrm{PM}} = (0.10 \\cdot CL_{CYP2D6, EM}) + CL_{non-CYP2D6}$$\n$$CL_{\\mathrm{PM}} = (0.10 \\cdot f_{m} \\cdot CL_{\\mathrm{EM}}) + ((1 - f_{m}) \\cdot CL_{\\mathrm{EM}})$$\nFactoring out $CL_{\\mathrm{EM}}$ gives:\n$$CL_{\\mathrm{PM}} = (0.10 \\cdot f_{m} + 1 - f_{m}) \\cdot CL_{\\mathrm{EM}}$$\n$$CL_{\\mathrm{PM}} = (1 - 0.90 \\cdot f_{m}) \\cdot CL_{\\mathrm{EM}}$$\nFrom this, the clearance ratio is:\n$$\\frac{CL_{\\mathrm{PM}}}{CL_{\\mathrm{EM}}} = 1 - 0.90 \\cdot f_{m}$$\nThis derived ratio quantifies the impact of the CYP2D6 polymorphism on total systemic clearance. The increased bioavailability in PMs ($F_{\\mathrm{PM}} > F_{\\mathrm{EM}}$) reflects the reduced first-pass metabolism in the liver, which is also a direct consequence of diminished CYP2D6 activity.\n\nWe can now substitute this clearance ratio back into our expression for the dose adjustment factor $R$:\n$$R = \\frac{F_{\\mathrm{EM}}}{F_{\\mathrm{PM}}} \\cdot (1 - 0.90 \\cdot f_{m})$$\nThis is the final derived expression for the oral dose adjustment factor.\n\nFinally, we calculate the numerical value of $R$ using the provided data:\n$F_{\\mathrm{EM}} = 0.50$\n$F_{\\mathrm{PM}} = 0.85$\n$f_{m} = 0.70$\n$CL_{\\mathrm{EM}} = 60 \\, \\mathrm{L/h}$ (This value is not needed for the ratio-based calculation of $R$, but was necessary for context and validation).\n\nSubstituting the values into the expression for $R$:\n$$R = \\frac{0.50}{0.85} \\cdot (1 - 0.90 \\cdot 0.70)$$\nFirst, calculate the term in the parentheses:\n$$1 - 0.90 \\cdot 0.70 = 1 - 0.63 = 0.37$$\nNow, substitute this back into the equation for $R$:\n$$R = \\frac{0.50}{0.85} \\cdot 0.37$$\n$$R \\approx 0.588235 \\times 0.37$$\n$$R \\approx 0.217647$$\nThe problem requires the answer to be rounded to three significant figures.\n$$R \\approx 0.218$$\nThus, a poor metabolizer should receive a dose that is approximately $0.218$ times the dose given to an extensive metabolizer to achieve the same total systemic exposure. This significant dose reduction is necessary to compensate for both the decreased systemic clearance and the increased oral bioavailability in the poor metabolizer phenotype.", "answer": "$$\\boxed{0.218}$$", "id": "4916997"}]}